PDF(Pubmed)
Abstract：
UNASSIGNED: Nearly half a million interbody fusions are estimated to be performed in the US each year, many of which involve complex reconstruction. The ability to limit seroma formation is vital to a seamless postoperative recovery.
UNASSIGNED: A retrospective review was performed for patients undergoing fusion procedures along with flap reconstruction over a period of 20 months. Cohorts reflect a temporal practice shift where use of hydrolyzed collagen powder (HCP) was initiated for hypothesized seroma prevention. Outcomes and associated metrics were used for intergroup comparison.
UNASSIGNED: The study included 76 patients, of whom 47 were treated with HCP and 29 were not. Control patients had significantly fewer postoperative seromas than experimental ones (6.9% vs 27.7%; P = .03). The cohorts had no significant differences in time until final drain removal or in number of spinal levels involved (7.8 vs 7.1 days; P = .33, 8.5 vs 8.4 levels; P = .90). Rates of wound dehiscence, hematoma, or infection did not differ significantly between control and experimental patients (3.4% vs 12.8%, P = .17; 0% vs 0%; and 6.9% vs 10.6%, P = .58, respectively).
UNASSIGNED: The use of HCP led to a 4-fold increase in postoperative seromas in patients undergoing spinal fusion with flap reconstruction. This was regardless of all analyzed demographic and procedural factors, with the exception of age, whereby control patients were found to be on average slightly younger than experimental counterparts.
UNASSIGNED: A retrospective review was performed for patients undergoing fusion procedures along with flap reconstruction over a period of 20 months. Cohorts reflect a temporal practice shift where use of hydrolyzed collagen powder (HCP) was initiated for hypothesized seroma prevention. Outcomes and associated metrics were used for intergroup comparison.
UNASSIGNED: The study included 76 patients, of whom 47 were treated with HCP and 29 were not. Control patients had significantly fewer postoperative seromas than experimental ones (6.9% vs 27.7%; P = .03). The cohorts had no significant differences in time until final drain removal or in number of spinal levels involved (7.8 vs 7.1 days; P = .33, 8.5 vs 8.4 levels; P = .90). Rates of wound dehiscence, hematoma, or infection did not differ significantly between control and experimental patients (3.4% vs 12.8%, P = .17; 0% vs 0%; and 6.9% vs 10.6%, P = .58, respectively).
UNASSIGNED: The use of HCP led to a 4-fold increase in postoperative seromas in patients undergoing spinal fusion with flap reconstruction. This was regardless of all analyzed demographic and procedural factors, with the exception of age, whereby control patients were found to be on average slightly younger than experimental counterparts.
摘要：
■估计每年在美国进行近50万次体内融合，其中许多涉及复杂的重建。限制血清肿形成的能力对于无缝的术后恢复至关重要。
■对接受融合手术并进行皮瓣重建的患者进行了20个月的回顾性研究。队列反映了暂时的实践转变，即开始使用水解胶原蛋白粉末（HCP）进行假设的血清肿预防。结果和相关指标用于组间比较。
■该研究包括76名患者，其中47人接受了HCP治疗，29人未接受治疗。对照组患者的术后血清瘤明显少于实验患者（6.9％vs27.7％；P=0.03）。队列在最终引流之前的时间或涉及的脊髓水平数量上没有显着差异（7.8比7.1天；P=.33，8.5比8.4水平；P=.90）。伤口开裂的比率,血肿,或感染在对照组和实验患者之间没有显着差异（3.4％vs12.8％，P=.17；0%对0%；6.9%对10.6%，分别为P=.58)。
■HCP的使用导致接受皮瓣重建的脊柱融合术的患者术后血清瘤增加了4倍。这与所有分析的人口统计学和程序因素无关，除了年龄,因此，发现对照组患者平均比实验患者年轻一些。
■对接受融合手术并进行皮瓣重建的患者进行了20个月的回顾性研究。队列反映了暂时的实践转变，即开始使用水解胶原蛋白粉末（HCP）进行假设的血清肿预防。结果和相关指标用于组间比较。
■该研究包括76名患者，其中47人接受了HCP治疗，29人未接受治疗。对照组患者的术后血清瘤明显少于实验患者（6.9％vs27.7％；P=0.03）。队列在最终引流之前的时间或涉及的脊髓水平数量上没有显着差异（7.8比7.1天；P=.33，8.5比8.4水平；P=.90）。伤口开裂的比率,血肿,或感染在对照组和实验患者之间没有显着差异（3.4％vs12.8％，P=.17；0%对0%；6.9%对10.6%，分别为P=.58)。
■HCP的使用导致接受皮瓣重建的脊柱融合术的患者术后血清瘤增加了4倍。这与所有分析的人口统计学和程序因素无关，除了年龄,因此，发现对照组患者平均比实验患者年轻一些。
